Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Financing Activities: 2021-2025

Historic Cash from Financing Activities for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $3.7 million.

  • Krystal Biotech's Cash from Financing Activities rose 10.22% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.5 million, marking a year-over-year decrease of 116.66%. This contributed to the annual value of $27.0 million for FY2024, which is 86.68% down from last year.
  • Per Krystal Biotech's latest filing, its Cash from Financing Activities stood at $3.7 million for Q3 2025, which was up 106.51% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Cash from Financing Activities ranged from a high of $202.1 million in Q4 2021 and a low of -$12.5 million during Q1 2025.
  • In the last 3 years, Krystal Biotech's Cash from Financing Activities had a median value of $3.4 million in 2024 and averaged $20.3 million.
  • Per our database at Business Quant, Krystal Biotech's Cash from Financing Activities skyrocketed by 15,527.14% in 2022 and then tumbled by 217.79% in 2025.
  • Over the past 5 years, Krystal Biotech's Cash from Financing Activities (Quarterly) stood at $202.1 million in 2021, then tumbled by 98.48% to $3.1 million in 2022, then dropped by 14.66% to $2.6 million in 2023, then decreased by 7.29% to $2.4 million in 2024, then increased by 10.22% to $3.7 million in 2025.
  • Its Cash from Financing Activities stands at $3.7 million for Q3 2025, versus $1.8 million for Q2 2025 and -$12.5 million for Q1 2025.